Should family physicians routinely screen for hypercholesterolemia in children? No: Universal screening has uncertain benefits and a high risk of harms

American Family Physician

Volumn 86, Issue 8, 2012, Pages 800-

  LeFevre, Michael ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; STATIN;

ATHEROSCLEROSIS; BODY MASS; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; FAMILY HISTORY; GENERAL PRACTITIONER; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MORBIDITY; MORTALITY; MYOPATHY; NATIONAL HEALTH ORGANIZATION; PUBERTY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCREENING; TREATMENT OUTCOME; GENERAL PRACTICE; MASS SCREENING; NOTE;

FAMILY PRACTICE; HUMANS; HYPERCHOLESTEROLEMIA; MASS SCREENING;

EID: 84868328916     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Editorial

References (7)

1. National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213-S256.
2. U.S. Preventive Services Task Force. Screening for lipid disorders in adults. June 2008. http://www.uspreventiveservicestaskforce.org/uspstf/uspschol.htm. Accessed September 13, 2012.
3. Barter PJ, Caulfield M, Eriksson M, et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122.
4. U.S. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed May 5, 2012.
5. de Ferranti S, Ludwig DS. Storm over statins-the controversy surrounding pharmacologic treatment of children. N Engl J Med. 2008;359(13):1309-1312.
6. Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;307(3):257-258.
7. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA. 2012;307(3):259-260.